SCHEMBL4245344

SCHEMBL4245344

O=C(NC(=O)N1CCC(CSc2ccccc2)CC1)c1ccc(O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.48
KMT2A Q03164 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.44
PPARG P37231 1/20 0.44
NCOA2 Q15596 1/20 0.44
NCOA1 Q15788 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
CHRM4 P08173 1/20 0.42
MAP1LC3B Q9GZQ8 1/20 0.42
MAP1LC3A Q9H492 1/20 0.42
TPSAB1 Q15661 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4239616 0.82 FAAH (0.61) KMT2APOLBGRIN2DGRIN3BGRIN1
SCHEMBL4245347 0.80 ALDH1A1 (0.44) GAAKMT2ASMN1; SMN2POLBPPARG
SCHEMBL4247834 0.79 GRIN2D (0.52) GAAKMT2ASMN1; SMN2CHRM4GRIN2D
SCHEMBL5371009 0.77 PKM (0.51) KMT2ASMN1; SMN2POLBPPARGNCOA2
SCHEMBL15477388 0.77 SMN1; SMN2 (0.48) SMN1; SMN2GRIN2BPKMALDH1A1
SCHEMBL8554777 0.76 ACHE (0.56) KMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL4240704 0.75 EPHX2 (0.55) GAAKMT2A
SCHEMBL4243146 0.73 CCR3 (0.49) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4247871 0.73 KMT2A (0.62) GAAKMT2ASMN1; SMN2POLBGRIN2D
SCHEMBL4243510 0.73 FAAH (0.56) KMT2APOLBGRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170901-A1 Benzoyl Urea Derivatives RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2009-07-02 US claimed
EP-1771429-A1 NEW BENZOYL UREA DERIVATIVES RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2007-04-11 EP claimed
WO-2006010966-A1 NEW BENZOYL UREA DERIVATIVES Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-02-02 WO claimed
US-20090170901-A1 Benzoyl Urea Derivatives RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2009-07-02 US disclosed
EP-1771429-A1 NEW BENZOYL UREA DERIVATIVES RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2007-04-11 EP disclosed
WO-2006010966-A1 NEW BENZOYL UREA DERIVATIVES Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170901-A1 Benzoyl Urea Derivatives OPRM1, GRIN2C, GRIN3A GAA 3604/4885KMT2A 3249/4885SMN1; SMN2 3077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.